- Subject Team
Wei Daolin
M.D., Ph.D., Associate Chief Physician
Diagnosis and treatment of anemia, hemorrhagic disorders, and hematological malignancies
Department of Hematology
Profile
Education & Training
11/2004-10/2007 Postdoctoral fellow
Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA,USA
09/2001-07/2004 Ph.D., Hematology
Shanghai Medical College, Fudan University, Shanghai, China
09/1995-07/1998 M.S., Medicine
Shanghai Medical University, Shanghai, China
09/1990-07/1995 M.D., Medicine
Nanjing Railway Medical College, Nanjing, Jiangsu Province, China
11/2004-10/2007 Postdoctoral fellow
Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA,USA
09/2001-07/2004 Ph.D., Hematology
Shanghai Medical College, Fudan University, Shanghai, China
09/1995-07/1998 M.S., Medicine
Shanghai Medical University, Shanghai, China
09/1990-07/1995 M.D., Medicine
Nanjing Railway Medical College, Nanjing, Jiangsu Province, China
Work Experiences:
07/2007--present Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
08/1998-
07/2001 Resident in Internal Medicine
Huadong Hospital, Shanghai, China
07/2007--present Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
08/1998-
07/2001 Resident in Internal Medicine
Huadong Hospital, Shanghai, China
Professional Memberships
Youth Member, Shanghai Medical Association Hematology Branch Committee, 2013-present
Youth Member, Shanghai Medical Association Hematology Branch Committee, 2013-present
Honors and Awards
2016 Annual Advanced Staff, Shanghai Institute of Hematology
2004 Outstanding graduate, Fudan University
2016 Annual Advanced Staff, Shanghai Institute of Hematology
2004 Outstanding graduate, Fudan University
Selected Publications
1. Wei D, Tong Y, Bai H, Cai Q, Gao Y, Wang C. A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma. Oncotarget. 2016;7(43):70168-70174.
2. Men Y, Sun X, Wei D, Yu Z. Primary extranodal head and neck classical Hodgkin lymphoma: A rare clinical case report. Exp Ther Med. 2016;12(2):1007-1011.
3. Wei D, Zhao C, Zhao M, Wei J, Gao Y, Cai Q, Wang C. Modified bortezomib-based combination therapy for multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2014; 35(9): 854-6.
4. Wei D, Pan X, Yan S, Gao Y, Cai Q, Wang C. Analysis of treatment strategies for management of elderly patients with acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2014;35(8):763-6.
5. Zhou L, Bai H, Wang C, Wei D, Qin Y, Xu X. microRNA‑125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep. 2014; 9(5): 1909-16.
6. Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402-8.
1. Wei D, Tong Y, Bai H, Cai Q, Gao Y, Wang C. A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma. Oncotarget. 2016;7(43):70168-70174.
2. Men Y, Sun X, Wei D, Yu Z. Primary extranodal head and neck classical Hodgkin lymphoma: A rare clinical case report. Exp Ther Med. 2016;12(2):1007-1011.
3. Wei D, Zhao C, Zhao M, Wei J, Gao Y, Cai Q, Wang C. Modified bortezomib-based combination therapy for multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2014; 35(9): 854-6.
4. Wei D, Pan X, Yan S, Gao Y, Cai Q, Wang C. Analysis of treatment strategies for management of elderly patients with acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2014;35(8):763-6.
5. Zhou L, Bai H, Wang C, Wei D, Qin Y, Xu X. microRNA‑125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep. 2014; 9(5): 1909-16.
6. Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402-8.